Angptl7, a member of the angiopoietin-like protein family, is involved in multiple biological processes. It has been associated with angiogenesis, inflammation, and is known to play a role in the regulation of insulin resistance, with potential implications in type 2 diabetes mellitus [4]. Additionally, it participates in the regulation of intra-ocular pressure (IOP), making it relevant in glaucoma research [1,3,5].

In mouse models, Angptl7 knockout (KO) mice have lower basal IOP compared to wild-type mice, with heterozygotes also showing a trend towards lower IOP [1]. Increasing murine Angptl7 levels via injection into mouse eyes increases IOP, and acute Angptl7 silencing in adult mice lowers the IOP, similar to the observations in KO mice [1]. In the context of acute myeloid leukemia (AML), knocking out Id1 in mesenchymal cells, which reduces Angptl7 levels, significantly suppresses the proliferation of cocultured AML cells and impairs AML progression in mouse models [2].

In conclusion, Angptl7 is crucial for IOP homeostasis and may be a therapeutic target for glaucoma. Its role in promoting insulin resistance suggests it could be relevant in diabetes-related research. The use of Angptl7 KO mouse models has provided key insights into its functions in IOP regulation and AML progression, highlighting its importance in these disease areas.